We are giving life to new classes of medicine to change the lives of patients with devastating diseases

We are giving life to new classes of medicine to change the lives of patients with devastating diseases

Strong track record of clinical success, outperforming the biopharma industry average by 6x1
0
New therapeutics and therapeutic candidates generated from PureTech's R&D engine
0
Taken from inception at PureTech to U.S. Food and Drug Administration approval
Unlocking the Potential of Validated Efficacy
We do this by enhancing on-target efficacy, enabling oral administration or improving tolerability to unlock new classes of medicine
Seasoned Senior Leadership
Our team has overseen R&D of therapeutics supporting more than 20 regulatory approvals and led several multi-billion dollar strategic transactions
Our network of scientific collaborators enables us to identify or co-invent key intellectual property before it's published in major journals
Our network of scientific collaborators enables us to identify or co-invent key intellectual property before it's published in major journals

News & Press

Press releases
2024-12-09
PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting
Press releases
2024-11-20
PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors